Inoviq Ltd has released a press release.
Appendix 4D and FY25 Half Year Financial Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Inoviq
- Quarterly Business Update and Appendix 4C - December 2024
- Weaponising Exosomes for Breast Cancer treatment
- Disease Specificity study completed for NeuCA15-3 test
- EXO-OC test delivers outstanding performance
- AGM CEO Presentation
Later from Inoviq
- Quarterly Business Update and Appendix 4C - March 2025
- Pause in Trade
- Response to ASX Price Query
- Suspension from Quotation
- Early Ovarian Cancer Screening Breakthrough
Follow Inoviq into a list and get an email when it puts out news.
Follow Inoviq